Allergan Accused of Keeping Generic Restasis Off the Market

Dallas, TX: Allergan could be facing a proposed antitrust class action lawsuit based on allegations made by direct purchases of the pharmaceutical company’s Restasis, a medication for dry eyes. The plaintiffs allege that Allergan blocked low-cost generic versions from entering the market.

The allegations state that had Allergan not been engaged in actions that delayed or stopped generic versions of Restasis from reaching the marking, those generic versions would have become available as early as May 2014, which could have been purchased at a fraction of the cost of Restasis.

Instead, the lawsuit alleges, Allergan has violated the Sherman Act by using a multifaceted approach to keep generics off the market. Its actions allegedly included blocking low-cost generics for the dry-eye medication through improperly obtained patents, sham infringement suits and citizen petitions, and partnering with a Native American tribe to avoid patent challenges.

Restasis Legal Help

If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on Nov-22-17